Trial Profile

This study is to preform a comparative pharmacokinetic study of Dronabinol XL AdVersa® versus the listed drug.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 04 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dronabinol (Primary)
Indications Chemotherapy-induced nausea and vomiting
Focus Pharmacokinetics; Registrational
Sponsors Tetra Bio Pharma

Most Recent Events

27 Sep 2018 According to a Tetra Bio Pharma media release, the company anticipates submitting a New Drug Application to commercialize PPP002 in Q1 2019.
13 Jun 2018 According to a Tetra Bio Pharma media release, if this trial proves the equivalence of test product to the reference product, the company anticipates filing for approval under 505(B)2 route in the USA in Q4 of 2018.
13 Jun 2018 According to a Tetra Bio Pharma media release, the company expects to launch this study in the third quarter of 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com